The press release is scientific and forward-looking with no immediate commercial catalyst. Traders should not expect a material stock move from this news alone. Monitor for future clinical adoption or partnership announcements.
Price Chart
Executive Summary
Aclarion announced that its Nociscan MRS technology was used in an award-winning research study exploring immune-associated biological signatures in chronic low back pain. The study is exploratory and does not represent a near-term commercial milestone or regulatory decision.
Key Facts
- Nociscan's MRS technology measured intradiscal propionic acid to identify immune-linked patient subtypes in Modic type 1 changes.
- The study received the 2026 ISSLS Best Paper Award and was conducted by University of Zurich, UCSF, and the REACH Center.
- Aclarion states the findings may expand Nociscan's clinical applications beyond surgical decision support, but this is early-stage research.
- No financial data, revenue, earnings, or guidance were provided in the press release.
Financial Impact
No near-term financial impact; study results are preliminary and do not affect current revenue or earnings.
Risk Factors
- The research is exploratory; no guarantee of clinical adoption or revenue generation.
- Forward-looking statements subject to regulatory and commercial risks.
- Small market cap ($8M) amplifies volatility on any news.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304126 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 9w ago | Insider Cluster | $2.77 $2.64 | ▼ −4.69% | ▼ −2.74% | $1.93 (−30.32%) |
Aug 18, 2026 9w ago | Insider Cluster | $2.60 $2.53 | ▼ −2.67% | ▼ −1.68% | $1.93 (−25.77%) |
Jun 9, 2026 19w ago | Press Release | $3.26 $2.99 | ▼ −8.28% | ▼ −9.73% | $1.93 (−40.80%) |
Jun 8, 2026 20w ago | Press Release | $3.36 $3.07 | ▼ −8.63% | ▼ −10.26% | $1.93 (−42.56%) |
Jun 3, 2026 20w ago | Press Release | $3.49 $3.09 | ▼ −11.46% | ▼ −10.46% | $1.93 (−44.70%) |
Jun 1, 2026 21w ago | Press Release | $3.37 $2.88 | ▼ −14.54% | ▼ −13.24% | $1.93 (−42.73%) |
May 6, 2026 24w ago | Insider Cluster | $3.28 $3.49 | ▲ +6.40% | ▲ +3.62% | $1.93 (−41.16%) |
May 5, 2026 24w ago | Press Release | $3.20 $3.50 | ▲ +9.38% | ▲ +4.42% | $1.93 (−39.69%) |
Apr 22, 2026 26w ago | Press Release | $3.73 $3.20 | ▼ −14.21% | ▼ −17.37% | $1.93 (−48.26%) |
Mar 19, 2026 31w ago | Press Release | $3.26 $3.39 | ▲ +3.99% | ▼ −3.63% | $1.93 (−40.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers